Application of urine proteomics for biomarker discovery in drug-induced liver injury

被引：32
作者：
van Swelm, Rachel P. L. [1 ]
Kramers, Cornelis [1 ]
Masereeuw, Rosalinde [1 ]
Russel, Frans G. M. [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, NL-6500 HB Nijmegen, Netherlands
来源：
CRITICAL REVIEWS IN TOXICOLOGY | 2014年 / 44卷 / 10期
关键词：
acetaminophen; diclofenac; fibrosis; gel electrophoresis; hepatocellular injury; idiosyncratic; LC-MS/MS; MALDI-TOF MS; methotrexate; oxidative stress; AMOXICILLIN-CLAVULANIC ACID; INDUCED HEPATIC-INJURY; INDUCED FULMINANT-HEPATITIS; DICLOFENAC-ASSOCIATED HEPATOTOXICITY; CARBON-TETRACHLORIDE HEPATOTOXICITY; MURINE ACETAMINOPHEN HEPATOTOXICITY; TAMOXIFEN-INDUCED STEATOHEPATITIS; NEUTROPHIL DEPLETION PROTECTS; LATENT TUBERCULOSIS INFECTION; FLIGHT MASS-SPECTROMETRY;
D O I：
10.3109/10408444.2014.931341
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
The leading cause of hepatic damage is drug-induced liver injury (DILI), for which currently no adequate predictive biomarkers are available. Moreover, for most drugs related to DILI, the mechanisms underlying the adverse reaction have not yet been elucidated. Urinary protein biomarker candidates for DILI have emerged in the past few years and correlate well with clinical studies for serum DILI biomarkers. The goal of this review was to investigate the use of urine as a source of protein biomarkers for drug-induced liver injury. Finally, we discuss some of the current strategies required to advance the field of biomarker discovery for DILI with respect to appropriate clinical biobanking and adequate translational research.
引用
收藏
页码：823 / 841
页数：19
相关论文
共 302 条
  • [81] Celecoxib-induced cholestatic hepatitis
    Galan, MV
    Gordon, SC
    Silverman, AL
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (03) : 254 - 254
  • [82] ACUTE HEPATITIS IN A PATIENT TREATED WITH CARBAMAZEPINE
    GALEONE, D
    LAMONTANARA, G
    TORELLI, D
    [J]. JOURNAL OF NEUROLOGY, 1985, 232 (05) : 301 - 303
  • [83] Discovery of Novel Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients: A Preliminary Study
    Gangadharan, Bevin
    Bapat, Manisha
    Rossa, Jan
    Antrobus, Robin
    Chittenden, David
    Kampa, Bettina
    Barnes, Eleanor
    Klenerman, Paul
    Dwek, Raymond A.
    Zitzmann, Nicole
    [J]. PLOS ONE, 2012, 7 (06):
  • [84] Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
    Gitlin, N
    Julie, NL
    Spurr, CL
    Lim, KN
    Juarbe, HM
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (01) : 36 - 38
  • [85] Gloria L, 1998, HEPATO-GASTROENTEROL, V45, P411
  • [86] A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
    Goldkind, L
    Laine, L
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (04) : 213 - 220
  • [87] Orthotopic liver transplantation with 100 hepatic allografts from donors over 60 years old
    González, FR
    Romero, CJ
    Romano, DR
    Segurola, CL
    Medina, EM
    Saborido, BP
    García, IG
    Cañete, AR
    González, EM
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (01) : 233 - 234
  • [88] Urinary Proteome Analysis of Irritable Bowel Syndrome (IBS) Symptom Subgroups
    Goo, Young Ah
    Cain, Kevin
    Jarrett, Monica
    Smith, Lynne
    Voss, Joachim
    Tolentino, Ernie
    Tsuji, Joyce
    Tsai, Yihsuan S.
    Panchaud, Alexandre
    Goodlett, David R.
    Shulman, Robert J.
    Heitkempert, Margaret
    [J]. JOURNAL OF PROTEOME RESEARCH, 2012, 11 (12) : 5650 - 5662
  • [89] Graham DJ, 2003, AM J GASTROENTEROL, V98, P175
  • [90] Liver enzyme monitoring in patients treated with troglitazone
    Graham, DJ
    Drinkard, CR
    Shatin, D
    Tsong, Y
    Burgess, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (07): : 831 - 833
45678910111213